Fred Alger Management’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-62,105
Closed -$609K – 483
2023
Q4
$609K Buy
+62,105
New +$508K ﹤0.01% 384
2023
Q3
– Sell
-69,780
Closed -$928K – 511
2023
Q2
$928K Buy
+69,780
New +$848K ﹤0.01% 380
2018
Q4
– Sell
-180,000
Closed -$974K – 558
2018
Q3
$974K Buy
+180,000
New +$772K ﹤0.01% 324
2016
Q4
– Sell
-10,000
Closed -$90K – 510
2016
Q3
$90K Buy
+10,000
New +$83.6K ﹤0.01% 384

Other funds holding PACB

Fred Alger Management's PACB Position: Q1 2024 in Review

Fred Alger Management sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 62,105 shares — an estimated $609K sold.

Fred Alger Management first reported a position in PACB in Q3 2016 and held it in 4 quarters. The position peaked at $974K in Q3 2018. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • Fred Alger Management reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • Fred Alger Management sold 62,105 Pacific Biosciences shares in Q1 2024, an estimated $609K.
  • Fred Alger Management first reported a position in Pacific Biosciences in Q3 2016 and held it in 4 quarters.
  • Fred Alger Management's Pacific Biosciences position peaked at $974K in Q3 2018.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Fred Alger Management's 13F filing for Q1 2024, filed 15 May 2024.